medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

# QUANTIFYING THE EFFECT OF ISOLATION AND NEGATIVE CERTIFICATION ON COVID-19 TRANSMISSION

**Jun-ichi Takeshita***
Research Institute of Science for Safety and Sustainability,
National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan

**Michio Murakami**
Center for Infectious Disease Education and Research,
Osaka University, Osaka, Japan

**Masashi Kamo**
Research Institute of Science for Safety and Sustainability,
National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan

**Wataru Naito**
Research Institute of Science for Safety and Sustainability,
National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan

**Tetsuo Yasutaka**
Research Institute for Geo-Resources and Environment, Geological Survey of Japan,
National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan

**Seiya Imoto**
Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science,
The University of Tokyo, Tokyo, Japan

February 21, 2022

## ABSTRACT

**Background** Isolation of close contact people and negative test certification are used to manage the spread of new coronavirus infections worldwide. These effectively prevent the spread of infection in advance, but they can lead to a decline in socio-economic activity. Thus, the present study quantified the extent to which isolation and negative test certification respectively reduce the risk of infection.

**Methods** A discrete-time SEIR model was used as the infectious disease model, and equations for calculating the conditional probability of non-infection status given negative test results on two different days were derived.

**Results** The respective non-infection probabilities with two negative PCR test results, and with one negative PCR test result and one antigen test result, were quantified. By substituting initial parameters of the SEIR model into these probabilities, the present study revealed the following: (1) isolating close contact individuals can reduce by $80\%$ the risk of infection during the first five days, but five more days are needed to reduce the risk $10\%$ more, and seven more days to reduce the risk $20\%$ more; and (2) if an individual with a negative PCR test result has a negative antigen test result the next day, then his or her infection probability is between $0.6\%$ and $0.7\%$.

*Corresponding author: jun-takeshita@aist.go.jp

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



**Conclusions** Five-day isolation has a proportionally greater effect on risk reduction, compared to longer isolation; and thus, if an isolation period of longer than five days is contemplated, both the risk reduction and the negative effects from such increased isolation should be considered. Regarding negative test certification, our results provide those in managerial positions, who must decide whether to accept the risk and hold mass-gathering events, with quantitative information that may be useful in their decision-making.

***Keywords*** SEIR model · Infection probability · Conditional probability · PCR test · Antigen test · Isolation period · Negative certification · COVID-19

# 1 Background

Risk management of new coronavirus infections has become a significant public health issue. Isolation of symptomatic individuals was insufficient to control the spread of infection, because some infected people were asymptomatic, and the contagious period commenced roughly two days before symptoms appeared [8]. This latter may be somewhat shorter in the case of the omicron strain [10], but it still exists. Insufficient control when an infected individual appeared led to the global spread of the coronavirus disease of 2019 (COVID-19), in addition to the high reproduction number of COVID-19; for example, 2.5 [4] or 3.15 [7] for the wild-type strain, 7 for the delta strain [7], and greater still for the omicron strain [5].

As a countermeasure against infectious diseases, tests targeting individuals, such as polymerase chain reaction (PCR) and antigen tests, are widely used. Mina *et al.* [12] noted that a higher frequency of low-sensitivity antigen testing contributed more to infection control than a lower frequency of high-sensitivity PCR testing, and Du *et al.* [6] discussed strategies for effective testing systems, based on cost-effectiveness analysis of the tests and universal isolation. However, testing the entire public presents difficulties in terms of cost and test resources.

In contrast, it is a common strategy to test only those people who seem to be infected and may contribute to the infection spread, when an infected individual is confirmed. One strategy is to identify people retrospectively who have met infected people, and test and isolate them. In Japan, people who had highly infectious contact behavior with an individual infected with COVID-19, during the contagious period, are considered close contact people [13]. Here, infectious contact behavior means contact with an infected person, within 1 meter for more than 15 minutes, without wearing a mask. The contagious period is from two days before the onset of illness to when the infected person is isolated after diagnosis. Then, even if the contact person has negative test results, they are mandated to stay at home and be monitored for 14 days from the day after the last day of contact. It should be noted that, with the appearance of the omicron strain, the above periods have been revised from time to time; and in the latest situation, the monitoring period has been reduced from 14 to 7 days. While this strategy effectively prevents the spread of infection in advance, it can lead to a decline in socio-economic activity.

Another strategy is to proactively identify groups whose acts could contribute to the spread of infection and allow contact behavior for those with negative PCR- or antigen-test certification. Typical examples are easing restrictions for traveling and participating in mass-gathering events based on negative test certification. In the Japanese professional soccer league, for example, when an infected player or team staff member is confirmed, only those certified negative by an antigen test, which provides the result on the same day, are allowed to take part in the game [16, p12]. However, it is not fully clear how these negative test certifications contribute to infection reduction.

Vaccination is currently progressing worldwide, and strategies to allow socio-economic activity through vaccination or negative test certification are being discussed [15]. It is important, then, to evaluate how reasonable it is to shorten the isolation period through negative test certification, and how much risk reduction is associated with negative test certification.

The present study had two aims. First, to investigate the reduction in infection risk through the use of negative test certification after an isolation period, and discuss possible reductions in the isolation period by combining the two most common tests. Second, to assess the extent to which negative antigen test results, without isolation, contribute to reducing the infection risk in a population that is likely to be infected.

# 2 Methods

## 2.1 Discrete SEIR Model

The present study applied a discrete-time Susceptible-Exposed-Infectious-Recovered (SEIR) model [9], in which individuals transition through five sequential statuses: susceptible ($S$), exposed ($E$), pre-symptomatic ($P$), infected ($I$),

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



and recovered ($R$), with the infected status subdivided into symptomatic ($I_s$) and asymptomatic ($I_a$), in one of which the infected individual is registered.

The average duration of each state, in days, was adopted from He *et al.* [8], rounded to the nearest integer: after an individual is exposed to the coronavirus, they are in Status $E$ for three days, Status $P$ for two days, Status $I_s$ or $I_a$ for seven days, and then remain in Status $R$ (Figure 1). Note that the first and second day of Status $P$ are denoted by $P_1$ and $P_2$, respectively; and there is a possibility of being infected by COVID-19 two or more times, but this possibility is omitted in the present study.

Let $S_0$, $E_0$, $P_{1,0}$, $P_{2,0}$, and $I_0$ be the initial populations of Statuses $S$, $E$, $P_1$, $P_2$, and $I$, respectively; and let day 0 be the initial day. Then the populations of day $k$ ($k = 1, 2, \ldots, 14$) can be easily calculated as in Table 1.

### 2.2 Two types of COVID19 tests

The present study deals with two types of tests (PCR and antigen tests) for determining whether an individual is infected with COVID-19. Kucirka *et al.* [11] and Brummer *et al.* [2] reported that the sensitivity depended on an individual's status. Let $a_1$, $a_2$, and $a_I$, then, be sensitivities of COVID-19 PCR tests for individual status $P_1$, $P_2$, and $I$, respectively. Then $a_1 = 0.33$, $a_2 = 0.67$, and $a_I = 0.80$. Further, let $b$ be the specificity of a COVID-19 PCR test for individual Statuses $S$ and $E$, then $b = 0.999$. Table 2 summarizes the sensitivity and specificity of COVID-19 PCR tests.

COVID-19 antigen tests have 0.7-times the sensitivity and the same specificity as PCR tests [3]. In other words, the sensitivities of antigen tests for individual Statuses $P_1$, $P_2$, and $I$ are $0.7a_1 = 0.23$, $0.7a_2 = 0.47$, and $0.7a_I = 0.56$, respectively; while the specificity for individual Statuses $S$ and $E$ is $b = 0.999$. Table 3 summarizes the sensitivity and specificity of COVID-19 antigen tests. It should be remarked that the sensitivity of antigen tests varies with the type of test, and can be less than 0.7 [14]. Further, in the case of the omicron strain, one study has reported that the sensitivity of nasal antigen tests is low within three days from onset [1].

### 2.3 Conditional probability of non-infection status given negative test results

Hereafter, let $\oplus_k$ and $\ominus_k$ be situations in which an individual has a positive and a negative PCR test result, respectively, on day $k$ ($i = 0, \ldots, 14$); and $\mathcal{P}(X|Y)$ represents the probability that the individual is in Status $X$ in Situation $Y$, where $X$ is one of $S$, $E$, $P_1$, $P_2$, $I$, $R$, or their union, and $Y$ is one of $\oplus_k$, $\ominus_k$, or their intersection.

#### 2.3.1 Conditional probability of non-infection status given one negative PCR test result

This clause derives the non-infected probability when an individual has a negative test result on day 0. In other words, $\mathcal{P}(S_0 \cup R_0|\ominus_0)$ is derived. Note that cursive script $\mathcal{P}$ stands for the probability, while capital letter $P$ stands for an individual's status. Let $S'_0 := S_0 \cup R_0$; that is, $S'_0$ means a non-infection status on day 0. Since the overall status on day 0, say $\Omega_0$, equals $S_0 \cup E_0 \cup P_{1,0} \cup P_{2,0} \cup I_0 \cup R_0$, the following holds from Bayes' theorem.

$$
\begin{aligned}
\mathcal{P}(S_0 \cup R_0|\ominus_0) =& \mathcal{P}(S'_0)P(\ominus_0|S'_0)/ \\
& \Big(\mathcal{P}(S'_0)\mathcal{P}(\ominus_0|S'_0) + \mathcal{P}(E_0)\mathcal{P}(\ominus_0|E_0) + \mathcal{P}(P_{1,0})\mathcal{P}(\ominus_0|P_{1,0}) \\
& \qquad + \mathcal{P}(P_{2,0})\mathcal{P}(\ominus_0|P_{2,0}) + \mathcal{P}(I_0)\mathcal{P}(\ominus_0|I_0)\Big) \\
& = b\mathcal{P}(S'_0)/ \\
& \Big(b\mathcal{P}(S'_0) + b\mathcal{P}(E_0) + (1-a_1)\mathcal{P}(P_{1,0}) \\
& \qquad + (1-a_2)\mathcal{P}(P_{2,0}) + (1-a_s)\mathcal{P}(Is_0)\Big).
\end{aligned}
$$

#### 2.3.2 Conditional probability of non-infected status given two negative PCR test results

This clause derives the non-infection probability when an individual has a negative PCR test result on both day 0 and day $k$ $k$ ($1 \leq k \leq 14$). In other words, $\mathcal{P}(S_k \cup R_k|\ \ominus_0 \cap \ominus_k)$ is derived. Let $S'_k := S_k \cup R_k$; that is, $S'_k$ indicates

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



non-infection status at day $k$ ($0 \leq k \leq 14$). First, from Bayes' theorem, the following holds.

$$\begin{aligned}
&\mathcal{P}\big(S_k \cup R_k \big| \ominus_0 \cap \ominus_k \big) \\
&\quad = \mathcal{P}(S'_k)\mathcal{P}(\ominus_0 \cap \ominus_k | S'_k) \Big/ \\
&\qquad \Big(\mathcal{P}(S'_k)\mathcal{P}(\ominus_0 \cap \ominus_k | S'_k) + \mathcal{P}(E_k)\mathcal{P}(\ominus_0 \cap \ominus_k | E_k) \\
&\qquad\quad + \mathcal{P}(P_{1,k})\mathcal{P}(\ominus_0 \cap \ominus_k | P_{1,k}) + \mathcal{P}(P_{2,k})\mathcal{P}(\ominus_0 \cap \ominus_k | P_{2,k}) \\
&\qquad\quad + \mathcal{P}(I_k)\mathcal{P}(\ominus_0 \cap \ominus_k | I_k)\Big). \qquad (1)
\end{aligned}$$

Next, in order to calculate (1), $\mathcal{P}(S'_k)\mathcal{P}(\ominus_0 \cap \ominus_k | S'_k)$ is derived. By the definitions of the conditional probability and $\Omega_0$,

$$\mathcal{P}(S'_k)\mathcal{P}(\ominus_0 \cap \ominus_k | S'_k) = \mathcal{P}(\ominus_0 \cap \ominus_k \cap S'_k \cap \Omega_0). \qquad (2)$$

Then, from De Morgan's laws, the following holds.

$$\begin{aligned}
(2) &= \mathcal{P}\big(\ \ominus_0 \cap \ominus_k \cap S'_k \cap (S'_0 \cup E_0 \cup P_{1,0} \cup P_{2,0} \cup I_0)\big) \\
&= \mathcal{P}\Big((\ominus_0 \cap \ominus_k \cap S'_k \cap S'_0) \cup (\ominus_0 \cap \ominus_k \cap S'_k \cap E_0) \\
&\qquad\qquad \cup \big(\ \ominus_0 \cap \ominus_k \cap S'_k \cap P_{1,0}\big) \cup \big(\ \ominus_0 \cap \ominus_k \cap S'_k \cap P_{2,0}\big) \\
&\qquad\qquad \cup \big(\ \ominus_0 \cap \ominus_k \cap S'_k \cap I_0\big)\Big) \\
&= \mathcal{P}(\ominus_0 \cap \ominus_k \cap S'_k \cap S'_0) + \mathcal{P}(\ominus_0 \cap \ominus_k \cap S'_k \cap E_0) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k \cap S'_k \cap P_{1,0}) + \mathcal{P}(\ominus_0 \cap \ominus_k \cap S'_k \cap P_{2,0}) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k \cap S'_k \cap I_0) \\
&= \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap S'_0)\mathcal{P}(S'_k \cap S'_0) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap E_0)\mathcal{P}(S'_k \cap E_0) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap P_{1,0})\mathcal{P}(S'_k \cap P_{1,0}) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap P_{2,0})\mathcal{P}(S'_k \cap P_{2,0}) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap I_0)\mathcal{P}(S'_k \cap I_0) \\
&= \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap S'_0)\mathcal{P}(S'_0)\mathcal{P}(S'_k | S'_0) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap E_0)\mathcal{P}(E_0)\mathcal{P}(S'_k | E_0) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap P_{1,0})\mathcal{P}(P_{1,0})\mathcal{P}(S'_k | P_{1,0}) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap P_{2,0})\mathcal{P}(P_{2,0})\mathcal{P}(S'_k | P_{2,0}) \\
&\qquad\qquad + \mathcal{P}(\ominus_0 \cap \ominus_k | S'_k \cap I_0)\mathcal{P}(I_0)\mathcal{P}(S'_k | I_0). \qquad (3)
\end{aligned}$$

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



In the same way, the following hold.

$$
\begin{aligned}
\mathcal{P}(E_k)\mathcal{P}(\ominus_0 \cap \ominus_k | E_k) = {} & \mathcal{P}\left(\ominus_0 \cap \ominus_k | E_k \cap S_0'\right) \mathcal{P}(S_0')\mathcal{P}(E_k|S_0') \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | E_k \cap E_0\right) \mathcal{P}(E_0)\mathcal{P}(E_k|E_0) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | E_k \cap P_{1,0}\right) \mathcal{P}(P_{1,0})\mathcal{P}(E_k|P_{1,0}) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | E_k \cap P_{2,0}\right) \mathcal{P}(P_{2,0})\mathcal{P}(E_k|P_{2,0}) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | E_k \cap I_0\right) \mathcal{P}(I_0)\mathcal{P}(E_k|I_0) \\
\mathcal{P}(P_{1,k})\mathcal{P}(\ominus_0 \cap \ominus_k | P_{1,k}) = {} & \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{1,k} \cap S_0'\right) \mathcal{P}(S_0')\mathcal{P}(P_{1,k}|S_0') \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{1,k} \cap E_0\right) \mathcal{P}(E_0)\mathcal{P}(P_{1,k}|E_0) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{1,k} \cap P_{1,0}\right) \mathcal{P}(P_{1,0})\mathcal{P}(P_{1,k}|P_{1,0}) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{1,k} \cap P_{2,0}\right) \mathcal{P}(P_{2,0})\mathcal{P}(P_{1,k}|P_{2,0}) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{1,k} \cap I_0\right) \mathcal{P}(I_0)\mathcal{P}(P_{1,k}|I_0) \\
\mathcal{P}(P_{2,k})\mathcal{P}(\ominus_0 \cap \ominus_k | P_{2,k}) = {} & \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{2,k} \cap S_0'\right) \mathcal{P}(S_0')\mathcal{P}(P_{2,k}|S_0') \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{2,k} \cap E_0\right) \mathcal{P}(E_0)\mathcal{P}(P_{2,k}|E_0) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{2,k} \cap P_{1,0}\right) \mathcal{P}(P_{1,0})\mathcal{P}(P_{2,k}|P_{1,0}) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{2,k} \cap P_{2,0}\right) \mathcal{P}(P_{2,0})\mathcal{P}(P_{2,k}|P_{2,0}) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | P_{2,k} \cap I_0\right) \mathcal{P}(I_0)\mathcal{P}(P_{2,k}|I_0) \\
\mathcal{P}(I_k)\mathcal{P}(\ominus_0 \cap \ominus_k | I_k) = {} & \mathcal{P}\left(\ominus_0 \cap \ominus_k | I_k \cap S_0'\right) \mathcal{P}(S_0')\mathcal{P}(I_k|S_0') \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | I_k \cap E_0\right) \mathcal{P}(E_0)\mathcal{P}(I_k|E_0) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | I_k \cap P_{1,0}\right) \mathcal{P}(P_{1,0})\mathcal{P}(I_k|P_{1,0}) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | I_k \cap P_{2,0}\right) \mathcal{P}(P_{2,0})\mathcal{P}(I_k|P_{2,0}) \\
& + \mathcal{P}\left(\ominus_0 \cap \ominus_k | I_k \cap I_0\right) \mathcal{P}(I_0)\mathcal{P}(I_k|I_0).
\end{aligned} \tag{4}
$$

Finally, by substituting (3)–(4) into (1), the desired probability can be derived.

## 3 Results

### 3.1 Non-infection probability under a negative PCR test result on both day $0$ and day $k$

#### 3.1.1 The case where $k = 1$

From Table 1, the following relationships between the day $0$ and day $1$ statuses hold.

$$
\mathcal{P}(S_1 \cup R_1) = \mathcal{P}(S_0 \cup R_0) + \frac{1}{7}\mathcal{P}(I_0), \qquad \mathcal{P}(E_1) = \frac{2}{3}\mathcal{P}(E_0),
$$
$$
\mathcal{P}(P_{1,1}) = \frac{1}{3}\mathcal{P}(E_0), \qquad \mathcal{P}(P_{2,1}) = \mathcal{P}(P_{1,0}), \quad \text{and} \quad \mathcal{P}(I_1) = \mathcal{P}(P_{2,0}) + \frac{6}{7}\mathcal{P}(I_0).
$$

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Therefore, the members on the right-hand side of (1) can be calculated as follows.

$$\begin{aligned}
\mathcal{P}(S_1')\mathcal{P}(\ominus_0 \cap \ominus_1 | S_1') &= \mathcal{P}\left(\ominus_0 \cap \ominus_1 | S_1' \cap S_0'\right)\mathcal{P}(S_0')\mathcal{P}(S_1'|S_0') \\
&\quad + \mathcal{P}\left(\ominus_0 \cap \ominus_1 | S_1' \cap I_0\right)\mathcal{P}(I_0)\mathcal{P}(S_1'|I_0) \\
&= b^2\mathcal{P}(S_0') + \frac{1}{7}b(1-a_I)\mathcal{P}(I_0) \qquad (5) \\
\mathcal{P}(E_1)\mathcal{P}(\ominus_0 \cap \ominus_1 | E_1) &= \mathcal{P}\left(\ominus_0 \cap \ominus_1 | E_1 \cap E_0\right)\mathcal{P}(E_0)\mathcal{P}(E_2|E_0) \\
&= \frac{2}{3}b^2\mathcal{P}(E_0) \\
\mathcal{P}(P_{1,1})\mathcal{P}(\ominus_0 \cap \ominus_1 | P_{1,1}) &= \mathcal{P}\left(\ominus_0 \cap \ominus_1 | P_{1,1} \cap E_0\right)\mathcal{P}(E_0)\mathcal{P}(P_{1,1}|E_0) \\
&= \frac{1}{3}b(1-a_1)\mathcal{P}(E_0) \\
\mathcal{P}(P_{2,1})\mathcal{P}(\ominus_0 \cap \ominus_1 | P_{2,1}) &= \mathcal{P}\left(\ominus_0 \cap \ominus_1 | P_{2,1} \cap P_{1,0}\right)\mathcal{P}(P_{1,0})\mathcal{P}(P_{2,1}|P_{1,0}) \\
&= (1-a_1)(1-a_2)\mathcal{P}(I_{1,0}) \\
\mathcal{P}(I_1)\mathcal{P}(\ominus_0 \cap \ominus_1 | I_1) &= \mathcal{P}\left(\ominus_0 \cap \ominus_1 | I_1 \cap P_{2,0}\right)\mathcal{P}(P_{2,0})\mathcal{P}(I_1|P_{2,0}) \\
&\quad + \mathcal{P}\left(\ominus_0 \cap \ominus_1 | I_1 \cap I_0\right)\mathcal{P}(I_0)\mathcal{P}(I_1|I_0) \\
&= (1-a_2)(1-a_I)\mathcal{P}(P_{2,0}) + \frac{6}{7}(1-a_I)^2\mathcal{P}(I_0). \qquad (6)
\end{aligned}$$

By substituting (5)–(6) and $k = 1$ into (1), the desired probability can be derived as follows.

$$\begin{aligned}
&\mathcal{P}\big(S_1 \cup R_1 \big| \ominus_0 \cap \ominus_1\big) \\
&= \left(b^2\mathcal{P}(S_0') + \frac{1}{7}b(1-a_I)\mathcal{P}(I_0)\right) \Big/ \\
&\quad \Bigg(b^2\mathcal{P}(S_0') + \frac{1}{7}b(1-a_I)\mathcal{P}(I_0) \\
&\qquad + \frac{2}{3}b^2\mathcal{P}(E_0) + \frac{1}{3}b(1-a_1)\mathcal{P}(E_0) + (1-a_1)(1-a_2)\mathcal{P}(P_{1,0}) \\
&\qquad + (1-a_2)(1-a_I)\mathcal{P}(P_{2,0}) + \frac{6}{7}(1-a_I)^2\mathcal{P}(I_0)\Bigg). \qquad (7)
\end{aligned}$$

In the same way, the non-infection probability for an individual with a negative PCR test result on both day $0$ and day $k$ for any $k(= 2, \ldots, 14)$ can be derived. Only the results are shown in the following clauses.

#### 3.1.2 The case where $k = 2$

$$\begin{aligned}
&\mathcal{P}\big(S_2 \cup R_2 \big| \ominus_0 \cap \ominus_2\big) \\
&= \left(b^2\mathcal{P}(S_0') + \frac{2}{7}b(1-a_2)\mathcal{P}(I_0)\right) \Big/ \\
&\quad \Bigg(b^2\mathcal{P}(S_0') + \frac{2}{7}b(1-a_2)\mathcal{P}(I_0) + \frac{1}{3}b^2\mathcal{P}(E_0) \\
&\qquad + \frac{1}{3}b(1-a_1)\mathcal{P}(E_0) + \frac{1}{3}b(1-a_2)\mathcal{P}(E_0) + (1-a_1)(1-a_I)\mathcal{P}(P_{1,0}) \\
&\qquad + (1-a_2)(1-a_I)\mathcal{P}(P_{2,0}) + \frac{5}{7}(1-a_I)^2\mathcal{P}(I_0)\Bigg).
\end{aligned}$$

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



#### 3.1.3 The case where $k = 3$

$$
\begin{aligned}
&\mathcal{P}\big(S_3 \cup R_3 \big| \ominus_0 \cap \ominus_3\big) \\
&= \left(b^2\mathcal{P}(S_0') + \frac{3}{7}b(1-a_2)\mathcal{P}(I_0)\right) \Big/ \\
&\quad \Bigg(b^2\mathcal{P}(S_0') + \frac{3}{7}b(1-a_2)\mathcal{P}(I_0) + \frac{1}{3}b(1-a_1)\mathcal{P}(E_0) \\
&\quad + \frac{1}{3}b(1-a_2)\mathcal{P}(E_0) + \frac{1}{3}b(1-a_I)\mathcal{P}(E_0) + (1-a_1)(1-a_I)\mathcal{P}(P_{1,0}) \\
&\quad + (1-a_2)(1-a_I)\mathcal{P}(P_{2,0}) + \frac{4}{7}(1-a_I)^2\mathcal{P}(I_0)\Bigg).
\end{aligned}
$$

#### 3.1.4 The case where $k = 4$

$$
\begin{aligned}
&\mathcal{P}\big(S_4 \cup R_4 \big| \ominus_0 \cap \ominus_4\big) \\
&= \left(b^2\mathcal{P}(S_0') + \frac{4}{7}b(1-a_2)\mathcal{P}(I_0)\right) \Big/ \\
&\quad \Bigg(b^2\mathcal{P}(S_0') + \frac{4}{7}b(1-a_2)\mathcal{P}(I_0) + \frac{1}{3}b(1-a_2)\mathcal{P}(E_0) \\
&\quad + \frac{2}{3}b(1-a_I)\mathcal{P}(E_0) + (1-a_1)(1-a_I)\mathcal{P}(P_{1,0}) \\
&\quad + (1-a_2)(1-a_I)\mathcal{P}(P_{2,0}) + \frac{3}{7}(1-a_I)^2\mathcal{P}(I_0)\Bigg).
\end{aligned}
$$

#### 3.1.5 The case where $k = 5$

$$
\begin{aligned}
&\mathcal{P}\big(S_5 \cup R_5 \big| \ominus_0 \cap \ominus_5\big) \\
&= \left(b^2\mathcal{P}(S_0') + \frac{5}{7}b(1-a_2)\mathcal{P}(I_0)\right) \Big/ \\
&\quad \Bigg(b^2\mathcal{P}(S_0') + \frac{5}{7}b(1-a_2)\mathcal{P}(I_0) + b(1-a_I)\mathcal{P}(E_0) \\
&\quad + (1-a_1)(1-a_I)\mathcal{P}(P_{1,0}) + (1-a_2)(1-a_I)\mathcal{P}(P_{2,0}) \\
&\quad + \frac{2}{7}(1-a_I)^2\mathcal{P}(I_0)\Bigg).
\end{aligned}
$$

#### 3.1.6 The case where $k = 6$

$$
\begin{aligned}
&\mathcal{P}\big(S_6 \cup R_6 \big| \ominus_0 \cap \ominus_6\big) \\
&= \left(b^2\mathcal{P}(S_0') + \frac{6}{7}b(1-a_2)\mathcal{P}(I_0)\right) \Big/ \\
&\quad \Bigg(b^2\mathcal{P}(S_0') + \frac{6}{7}b(1-a_2)\mathcal{P}(I_0) + b(1-a_I)\mathcal{P}(E_0) \\
&\quad + (1-a_1)(1-a_I)\mathcal{P}(P_{1,0}) + (1-a_2)(1-a_I)\mathcal{P}(P_{2,0}) \\
&\quad + \frac{1}{7}(1-a_I)^2\mathcal{P}(I_0)\Bigg).
\end{aligned}
$$

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



#### 3.1.7 The case where $k = 7$

$$\begin{aligned}
&\mathcal{P}\big(S_7 \cup R_7 \big| \ominus_0 \cap \ominus_7\,\big) \\
&= \Big(b^2\mathcal{P}(S_0') + b(1-a_I)\mathcal{P}(I_0)\Big)\Big/ \\
&\qquad \Big(b^2\mathcal{P}(S_0') + b(1-a_I)\mathcal{P}(I_0) + b(1-a_I)\mathcal{P}(E_0) \\
&\qquad\qquad + (1-a_1)(1-a_I)\mathcal{P}(P_{1,0}) + (1-a_2)(1-a_I)\mathcal{P}(P_{2,0})\Big).
\end{aligned}$$

#### 3.1.8 The case where $k = 8$

$$\begin{aligned}
&\mathcal{P}\big(S_8 \cup R_8 \big| \ominus_0 \cap \ominus_8\,\big) \\
&= \Big(b^2\mathcal{P}(S_0') + b(1-a_2)\mathcal{P}(P_{2,0}) + b(1-a_I)\mathcal{P}(I_0)\Big)\Big/ \\
&\qquad \Big(b^2\mathcal{P}(S_0') + b(1-a_2)\mathcal{P}(P_{2,0}) + b(1-a_I)\mathcal{P}(I_0) \\
&\qquad\qquad + b(1-a_I)\mathcal{P}(E_0) + (1-a_1)(1-a_I)\mathcal{P}(P_{1,0})\Big).
\end{aligned}$$

#### 3.1.9 The case where $k = 9$

$$\begin{aligned}
&\mathcal{P}\big(S_9 \cup R_9 \big| \ominus_0 \cap \ominus_9\,\big) \\
&= \Big(b^2\mathcal{P}(S_0') + b(1-a_1)\mathcal{P}(P_{1,0}) + b(1-a_2)\mathcal{P}(P_{2,0}) + b(1-a_I)\mathcal{P}(I_0)\Big)\Big/ \\
&\qquad \Big(b^2\mathcal{P}(S_0') + b(1-a_1)\mathcal{P}(P_{1,0}) + b(1-a_2)\mathcal{P}(P_{2,0}) \\
&\qquad\qquad + b(1-a_I)\mathcal{P}(I_0) + b(1-a_I)\mathcal{P}(E_0)\Big).
\end{aligned}$$

#### 3.1.10 The case where $k = 10$

$$\begin{aligned}
&\mathcal{P}\big(S_10 \cup R_10 \big| \ominus_0 \cap \ominus_1\, 0\big) \\
&= \Big(b^2\mathcal{P}(S_0') + \frac{1}{3}b^2\mathcal{P}(E_0) + b(1-a_1)\mathcal{P}(P_{1,0}) \\
&\qquad + b(1-a_2)\mathcal{P}(P_{2,0}) + b(1-a_I)\mathcal{P}(I_0)\Big)\Big/ \\
&\qquad \Big(b^2\mathcal{P}(S_0') + \frac{1}{3}b^2\mathcal{P}(E_0) + b(1-a_1)\mathcal{P}(P_{1,0}) + b(1-a_2) \\
&\qquad\qquad + \mathcal{P}(P_{2,0}) + b(1-a_I)\mathcal{P}(I_0) + \frac{2}{3}b(1-a_I)\mathcal{P}(E_0)\Big).
\end{aligned}$$

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



#### 3.1.11 The case where $k = 11$

$$\begin{aligned}
&\mathcal{P}\big(S_{11} \cup R_{11} \big| \ominus_0 \cap \ominus_{11}\big) \\
&= \Big(b^2\mathcal{P}(S_0') + \frac{2}{3}b^2\mathcal{P}(E_0) + b(1-a_1)\mathcal{P}(P_{1,0}) \\
&\quad + b(1-a_2)\mathcal{P}(P_{2,0}) + b(1-a_I)\mathcal{P}(I_0)\Big) \Big/ \\
&\quad \Big(b^2\mathcal{P}(S_0') + \frac{2}{3}b^2\mathcal{P}(E_0) + b(1-a_1)\mathcal{P}(P_{1,0}) + b(1-a_2)\mathcal{P}(P_{2,0}) \\
&\quad + b(1-a_I)\mathcal{P}(I_0) + \frac{1}{3}b(1-a_I)\mathcal{P}(E_0)\Big).
\end{aligned}$$

#### 3.1.12 The case where $k = 12, 13$, and $14$

Since every individual is in Status $R$ after day 12, $\mathcal{P}\big(S_{12} \cup R_{12} \big| \ominus_0 \cap \ominus_{12}\big)$ , $\mathcal{P}\big(S_{13} \cup R_{13} \big| \ominus_0 \cap \ominus_{13}\big)$, and $\mathcal{P}\big(S_{14} \cup R_{14} \big| \ominus_0 \cap \ominus_{14}\big)$ are identical.

$$\begin{aligned}
&\mathcal{P}\big(S_{12} \cup R_{12} \big| \ominus_0 \cap \ominus_{12}\big) = \mathcal{P}\big(S_{13} \cup R_{13} \big| \ominus_0 \cap \ominus_{13}\big) = \mathcal{P}\big(S_{14} \cup R_{14} \big| \ominus_0 \cap \ominus_{14}\big) \\
&= \Big(b^2\mathcal{P}(S_0') + b^2\mathcal{P}(E_0) + b(1-a_1)\mathcal{P}(P_{1,0}) \\
&\quad + b(1-a_2)\mathcal{P}(P_{2,0}) + b(1-a_I)\mathcal{P}(I_0)\Big) \Big/ \\
&\quad \Big(b^2\mathcal{P}(S_0') + b^2\mathcal{P}(E_0) + b(1-a_1)\mathcal{P}(P_{1,0}) \\
&\quad + b(1-a_2)\mathcal{P}(P_{2,0}) + b(1-a_I)\mathcal{P}(I_0)\Big) = 1.
\end{aligned} \tag{8}$$

### 3.2 Non-infection probability with one negative PCR test result and one negative antigen test result

Since the sensitivity of COVID-19 antigen tests are $0.7$ times that of COVID-19 PCR tests, we can obtain the probability $\mathcal{P}(S_1 \cup R_1 \big| \ominus_0 \cap \ominus_1^A)$ in a manner similar to the derivation of (7), but with $\ominus_1^A$ indicating that an individual has a negative antigen test result on day 1.

$$\begin{aligned}
&\mathcal{P}\big(S_1 \cup R_1 \big| \ominus_0 \cap \ominus_1^A\big) \\
&= \Big(b^2\mathcal{P}(S_0') + \frac{1}{7}b(1-a_I)\mathcal{P}(I_0)\Big) \Big/ \\
&\quad \Big(b^2\mathcal{P}(S_0') + \frac{1}{7}b(1-a_I)\mathcal{P}(I_0) + \frac{2}{3}b^2\mathcal{P}(E_0) + \frac{1}{3}b(1-0.7a_1)\mathcal{P}(E_0) \\
&\quad + (1-a_1)(1-0.7a_2)\mathcal{P}(P_{1,0}) + (1-a_2)(1-0.7a_I)\mathcal{P}(P_{2,0}) \\
&\quad + \frac{6}{7}(1-a_I)(1-0.7a_I)\mathcal{P}(I_0)\Big).
\end{aligned} \tag{9}$$

### 3.3 Infection probability of isolated people

This subsection demonstrates the respective infection probabilities for the following two-types of close contact people after a certain isolation period:

**(i)** isolated when an individual with a positive PCR test result appears in the community;

**(ii)** isolated when a symptomatic individual appears.

In order to demonstrate numerical results, the present study applied the initial-population parameters in Kamo *et al.* [**?** ]. For case (i),

$$\begin{aligned}
&\mathcal{P}(S_0) = 0.9808,\ \mathcal{P}(E_0) = 0.005111,\ \mathcal{P}(P_{1,0}) = 0.0025502, \\
&\mathcal{P}(P_{2,0}) = 0.003292,\ \text{and}\ \mathcal{P}(Is_0) = 0.008218;
\end{aligned} \tag{10}$$

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



while, for case (ii),

$$\mathcal{P}(S_0) = 0.98075,\ \mathcal{P}(E_0) = 0.0048505,\ \mathcal{P}(P_{1,0}) = 0.001258,$$
$$\mathcal{P}(P_{2,0}) = 0.0010239,\ \text{and}\ \mathcal{P}(Is_0) = 0.001211. \tag{11}$$

By substituting $a_1$, $a_2$, $a_I$, and (10) or (11) into (7)–(8), and subtracting them from 1, we obtain estimates of the infection probabilities on day $k$ for an individual with a negative PCR test result on both day 0 and day $k$. Table 4 shows these probabilities, and Figure 2 presents the same information using a scatter plot. In the graph, for $x \neq 0$, the $x$-axis represents the day when an individual takes the second PCR test, and the $y$-axis the infection probability for an individual with a negative PCR test result on both day 0 and day $x$. For $x = 0$, the corresponding $y$ value represents the infection probability for an individual with a negative PCR test result on day 0. The dots show the infection probabilities for Case (i), and the squares for Case (ii). The solid and dashed lines connect the dots and squares, respectively.

### 3.4 Infection probability of close contact people

#### 3.4.1 Infection probability of close contact people with two negative PCR tests

This clause assumes that 0.25 of the total population are close contact people, and $p$ of the total number of infected people are close contact people. Then the initial-population parameters are, for Case (i),

$$\mathcal{P}(S_0) = 1 - 0.07668p,\ \mathcal{P}(E_0) = 0.02044p,$$
$$\mathcal{P}(P_{1,0}) = 0.01020p,\ \mathcal{P}(P_{2,0}) = 0.01316p,\ \text{and}\ \mathcal{P}(Is_0) = 0.003287p; \tag{12}$$

while, for Case (ii),

$$\mathcal{P}(S_0) = 1 - 0.07669p,\ \mathcal{P}(E_0) = 0.0194p,$$
$$\mathcal{P}(P_{1,0}) = 0.005033p,\ \mathcal{P}(P_{2,0}) = 0.004096p,\ \text{and}\mathcal{P}(Is_0) = 0.004846p. \tag{13}$$

When the proportion $p$ is varied, Table 5 shows the initial populations of close contact people who are isolated at the appearance of an individual with a positive PCR test result (Case (i-Cls)) or who is symptomatic (Case (ii-Cls)).

By substituting $a_1$, $a_2$, $a_I$, and (12) or (13) into (7)–(8), and subtracting them from 1, we obtain estimates of the infection probabilities on day $k$ for an isolated individual with a negative PCR test result on both day 0 and day $k$, for the cases where $p = 0.25$, 0.30, 0.50, 0.60, and 0.90. Tables 6 and 7 show these infection probabilities for Case (i-Cls) and Case (ii-Cls), respectively; and Figures 3 and 4 present the same information using scatter plots. In these graphs, the $x$-axes represent the day where an individual takes the second PCR test (except $x = 0$), while the $y$-axes represent the infection probability (in the case of $x = 0$, the infection probability for an individual with a negative PCR test result on day 0).

#### 3.4.2 Infection probability of close contact people with one negative PCR test and one negative antigen test

Using the same conditions as in the previous clause, this clause deals with the situation where an individual takes a COVID-19 antigen test on day 1. Also, for each $p$, the infection probabilities of people with a negative PCR test result on day 1 and a negative antigen test result on day 0 are compared to those of people with negative PCR test results on both day 0 and day 1.

By substituting $a_1$, $a_2$, $a_I$, and (10) or (11) into (9), and subtracting it from 1, we obtain estimates of the infection probabilities on day 1 for an individual with a negative PCR test result on day 0 and a negative antigen test result on day 1. Table 8 shows these infection probabilities and the comparison with the case where an individual has negative PCR test results on both day 0 and day 1. In the table, $\Delta$ stands for the increment in the infection probability when the test type on day 1 is changed from a PCR to an antigen test.

By substituting $a_1$, $a_2$, $a_I$, and (12) or (13) into (9), and subtracting it from 1, we obtain estimates of the infection probabilities on day 1 for an isolated individual with a negative PCR test result on day 0 and a negative antigen test result on day 1, for the cases where $p = 0.25$, 0.30, 0.50, 0.60, and 0.90. Table 9 shows these infection probabilities and the comparison with the case where an individual has a negative PCR test result on both day 0 and day 1, for both Case (i-Cls) and Case (ii-Cls). In the table, $\Delta$ stands for a similar increment as in Table 8.

## 4 Discussion

### 4.1 Reduction of the isolation period

As noted in the Introduction, in Japan, close contact people previously had to be isolated for 14 days from the last day of contact, but this period has been reduced from 14 to 7 days with the appearance of the omicron strain.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2 shows that the infection probability decreases sharply from day $0$ to day $5$, remains roughly the same from day $6$ to day $8$, and then decreases from day $9$ to day $12$, for both Case (i) and Case (ii). This tendency implies that a five-day isolation period could be chosen to reduce the isolation period with less increased risk. Reducing the isolation period from $14$ to $5$ days corresponds to allowing for the risk of a $0.17\%$ and a $0.14\%$ increase in the infection probability for Case (i) and Case (ii), respectively. In other words, the expected number of infected people in a group of $1,000$ people would be less than two for both cases. Reducing the period from $7$ to $5$ days corresponds to the risk of a roughly $0.01\%$ increase in the infection probability for both cases, meaning that the expected number of infected people in a group of $10,000$ people would be roughly one. These results suggest that if we consider a small group, the increased risk would be negligible in these cases.

Next, when close contact people constitute $25\%$ of a given group, Figures 3 and 4 show the same pattern as Figure 2. Therefore, here too, $5$ days are a candidate for a reduced isolation period. From Table 6, the reduction in Case (i-Cls) corresponds to allowing for the risk of a $0.17\%$, $0.21\%$, $0.35\%$, $0.43\%$, and $0.65\%$ increase in the infection probability for $p = 0.25$, $0.30$, $0.50$, $0.60$, and $0.90$, respectively. From Table 7, the reduction in Case (ii-Cls) corresponds to allowing for the risk of a $0.14\%$, $0.17\%$, $0.28\%$, $0.34\%$, and $0.52\%$ increase in the infection probability for $p = 0.25$, $0.30$, $0.50$, $0.60$, and $0.90$, respectively. As the infection probability on day $5$ is less than $20\%$ of that on day $0$, the five-day isolation period and double test would result in an $80\%$ risk reduction. In sum, the maximum expected number of infected people in a group of $1,000$ people is less than $7$ in every case. If one wants to achieve $90\%$ and $100\%$ risk reduction, the isolation period should be $10$ and $12$ days, respectively. This implies that we can eliminate $80\%$ of the risk during the first $5$ days but need $5$ more days to eliminate $10\%$ more and $7$ more days to eliminate $20\%$ more.

In summary, a five-day isolation period has a significantly greater per diem effect on risk reduction than longer isolation. Thus, if an isolation period of longer than five days is contemplated, both the risk reduction and the negative effects of such prolonged isolation should be considered; and in the case of the omicron strain, an even shorter period may be sufficient to reduce the risk, because the incubation period is shorter.

### 4.2 Effect of negative test certification

Consider a team, such as a Japanese professional soccer or baseball team, and the situation where

- all the members of the team take PCR tests on the day before a game;
- an individual with a positive test result appears, but the other individuals have negative test results; and
- the other individuals take antigen tests on game day, and individuals with negative antigen test results are allowed to participate in the game.

By applying the study's results for day $1$, we can discuss the effect of negative test certification in the above situation. Table 8 shows that the infection probability of an individual is between $0.6\%$ and $0.7\%$; that is, the infection probability for an individual with negative antigen test certification is very low. For example, when $30$ people with negative antigen test certification take part in a game, the probability that at least one of them is infected is about $20\%$ because $1-(1-0.006)^30 = 0.17$ and $1-(1-0.007)^30 = 0.23$. It is up to the manager to decide whether to accept this risk and continue with the game, but our results will help such officials, by providing them with such quantitative information, which may be useful for their decision-making. If PCR tests are used instead of antigen tests, the expected infection probability decreases by only about $0.1\%$; that is, there is little difference between the two tests in this situation.

It should be noted that our model assumes that the people in a given group are isolated until day $1$, but they are not isolated strictly from day $0$ to day $1$ in the above scenario. However, people's behavior can typically be well managed in the case of small groups, which means that the probability of a new infection appearing in that one day is almost negligible. Our result shows that administering an antigen test on game day can be useful for determining whether a game should be held, and which team members should be allowed to participate in the game, when an individual with a positive test result appears before the game. Further, this serves as an example of how inexpensive and rapid antigen tests can be applied effectively to implement commercial activities and avoid economic shutdowns.

## 5 Conclusions

The present study investigated, in the context of COVID-19 transmission:

- the relationship between the length of the isolation period and the expected infection probability; and
- the expected infection probability with negative antigen test certification.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



With regard to the first item, the study results suggest that a five-day isolation period is effective from the view of risk management; and that, if a longer period is contemplated, then both the effect on the risk reduction and the possible negative effects due to the longer isolation should be considered. Regarding the second item, the results provide quantitative information that may be useful for the decision-making of officials in managerial positions.

Finally, it should be noted that the study results were generated by a simple discrete-time SEIR model with averaged parameters based on the coronavirus information as of 2020; thus, the estimated infection probabilities and risk magnitudes are also averages as of 2020. If one wished to be especially careful, focusing on the 95th percentile or a sensitive population for example, the parameters should be reconsidered. Further, since viruses typically mutate, the parameters must be adjusted according to the latest situation. In particular, in the case of the omicron strain, it is important to utilize the latest data, as new information of the sort required to perform the same analysis as in the present study is being reported daily.

## Abbreviations

COVID-19: coronavirus disease of 2019; PCR: polymerase chain reaction; SEIR model: Susceptible-Exposed-Infectious-Recovered model

## References

[1] B. Adamson, R. Sikka, A. L. Wyllie, and P. Premsrirut. Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series. *medRxiv*, Jan. 2022. doi:10.1101/2022.01.04.22268770.

[2] L. E. Brümmer, S. Katzenschlager, M. Gaeddert, C. Erdmann, S. Schmitz, M. Bota, M. Grilli, J. Larmann, M. A. Weigand, N. R. Pollock, A. Macé, S. Carmona, S. Ongarello, J. A. Sacks, and C. M. Denkinger. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. *PLOS Medicine*, 18(8):e1003735, Aug. 2021. ISSN 1549-1676. doi:10.1371/journal.pmed.1003735.

[3] L. E. Brümmer, S. Katzenschlager, M. Gaeddert, C. Erdmann, S. Schmitz, M. Bota, M. Grilli, J. Larmann, M. A. Weigand, N. R. Pollock, A. Macé, S. Carmona, S. Ongarello, J. A. Sacks, and C. M. Denkinger. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. *PLOS Medicine*, 18(8):e1003735, Aug. 2021. ISSN 1549-1676. doi:10.1371/journal.pmed.1003735.

[4] T. K. Burki. Lifting of COVID-19 restrictions in the UK and the Delta variant. *The Lancet Respiratory Medicine*, 9(8):e85, Aug. 2021. ISSN 22132600. doi:10.1016/S2213-2600(21)00328-3.

[5] E. Callaway and H. Ledford. How bad is Omicron? What scientists know so far. *Nature*, 600(7888):197–199, Dec. 2021. ISSN 0028-0836, 1476-4687. doi:10.1038/d41586-021-03614-z.

[6] Z. Du, A. Pandey, Y. Bai, M. C. Fitzpatrick, M. Chinazzi, A. Pastore y Piontti, M. Lachmann, A. Vespignani, B. J. Cowling, A. P. Galvani, and L. A. Meyers. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: A modelling study. *The Lancet Public Health*, 6(3):e184–e191, Mar. 2021. ISSN 24682667. doi:10.1016/S2468-2667(21)00002-5.

[7] W. He, G. Y. Yi, and Y. Zhu. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis. *Journal of Medical Virology*, 92(11):2543–2550, Nov. 2020. ISSN 0146-6615, 1096-9071. doi:10.1002/jmv.26041.

[8] X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan, X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, L. Zhao, F. Zhang, B. J. Cowling, F. Li, and G. M. Leung. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine*, 26(5):672–675, May 2020. ISSN 1078-8956, 1546-170X. doi:10.1038/s41591-020-0869-5.

[9] H. W. Hethcote. The mathematics of infectious diseases. *SIAM Review*, 42(4):599–653, Jan. 2000. ISSN 0036-1445, 1095-7200. doi:10.1137/S0036144500371907.

[10] L. Jansen, B. Tegomoh, K. Lange, K. Showalter, J. Figliomeni, B. Abdalhamid, P. C. Iwen, J. Fauver, B. Buss, and M. Donahue. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021. *MMWR. Morbidity and Mortality Weekly Report*, 70(5152):1782–1784, Dec. 2021. ISSN 0149-2195, 1545-861X. doi:10.15585/mmwr.mm705152e3.

[11] L. M. Kucirka, S. A. Lauer, O. Laeyendecker, D. Boon, and J. Lessler. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. *Annals of Internal Medicine*, 173(4):262–267, Aug. 2020. ISSN 0003-4819, 1539-3704. doi:10.7326/M20-1495.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



[12] M. J. Mina, R. Parker, and D. B. Larremore. Rethinking Covid-19 test sensitivity — A strategy for containment. *New England Journal of Medicine*, 383(22):e120, Nov. 2020. ISSN 0028-4793, 1533-4406. doi:10.1056/NEJMp2025631.

[13] Ministry of Health, Labour and Welfare. Q&A on the new coronavirus (for the general public) (In Japanese). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/dengue_fever_qa_00001.html#Q3-3.

[14] J. L. Prince-Guerra, O. Almendares, L. D. Nolen, J. K. L. Gunn, A. P. Dale, S. A. Buono, M. Deutsch-Feldman, S. Suppiah, L. Hao, Y. Zeng, V. A. Stevens, K. Knipe, J. Pompey, C. Atherstone, D. P. Bui, T. Powell, A. Tamin, J. L. Harcourt, P. L. Shewmaker, M. Medrzycki, P. Wong, S. Jain, A. Tejada-Strop, S. Rogers, B. Emery, H. Wang, M. Petway, C. Bohannon, J. M. Folster, A. MacNeil, R. Salerno, W. Kuhnert-Tallman, J. E. Tate, N. J. Thornburg, H. L. Kirking, K. Sheiban, J. Kudrna, T. Cullen, K. K. Komatsu, J. M. Villanueva, D. A. Rose, J. C. Neatherlin, M. Anderson, P. A. Rota, M. A. Honein, and W. A. Bower. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020. *MMWR. Morbidity and Mortality Weekly Report*, 70(3):100–105, Jan. 2021. ISSN 0149-2195, 1545-861X. doi:10.15585/mmwr.mm7003e3.

[15] D. Sleat, K. Innes, and I. Parker. Are vaccine passports and covid passes a valid alternative to lockdown? *BMJ*, page n2571, Nov. 2021. ISSN 1756-1833. doi:10.1136/bmj.n2571.

[16] The Japanese professional soccer league. J.LEAGUE PUB Report 2021 (in Japanese). https://jlib.j-league.or.jp/-site_media/media/content/70/1/html5.html#page=1.

## Declarations

## Ethics approval and consent to participate

Not applicable

## Consent for publication

Not applicable

## Availability of data and materials

Not applicable

## Competing interests

Among the outside support for the study, WN and TY report a relationship with Kao Corporation (funding grants); and a relationship with the Nippon Professional Baseball Organization, Yomiuri Giants, Tokyo Yakult Swallows, Japan Professional Football League, and Japan Professional Basketball League (funding grants).

Other activities: the study was conducted as part of a comprehensive research project, comprising members from two private companies, Kao Corporation and NVIDIA Corporation, Japan; however, no authors in the study belong to these companies. MM, MK, WN, TY, and SI have attended the new Coronavirus Countermeasures Liaison Council, jointly established by the Nippon Professional Baseball Organization and Japan Professional Football League, as experts without remuneration. WN and TY are advisors to the Japan National Stadium and Japan Professional Football League. The other authors declare no competing interests. The findings and conclusions of this article are solely the responsibility of the authors, and do not represent the official views of any institution.

## Funding

Not applicable

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



## Authors' contributions

JT made substantial contributions to the design of the study and the analysis, and drafted the article. MM made substantial contributions to the conception and design of the study, and substantively revised the draft. MK made substantial contributions to the design of the study and the analysis. WN, TY, and SI made substantial contributions to the conception and design of the study. All the authors have approved the submitted version and agreed both to be personally accountable for the author's own contributions, and to ensure that questions related to the accuracy or integrity of any part of the study, even ones in which the author was not personally involved, are appropriately investigated and resolved, with the resolution documented in the literature.

## Acknowledgements

Not applicable

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



## Figures




Figure 1: Discrete-time SEIR model used in the present study

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






Figure 2: For $x \neq 0$, the $x$-axis represents the day when an individual takes the second PCR test, and the $y$-axis the infection probability for an individual with a negative PCR test result on both day $0$ and day $x$. For $x = 0$, the corresponding $y$ value represents the infection probability for an individual with a negative PCR test result on day $0$. The dots show the infection probabilities for Case (i), and the squares for Case (ii). The solid and dashed lines connect the dots and squares, respectively.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






Figure 3: For $x \neq 0$, the $x$-axis represents the day when an individual takes the second PCR test, and the $y$-axis the infection probability for an individual with a negative PCR test result on both day $0$ and day $x$, for Case (i-Cls). For $x = 0$, the corresponding y value represents the infection probability for an individual with a negative PCR test result on day $0$, for Case (i-Cls). The dots, squares, diamonds, upward triangles, and downward triangles show the infection probabilities for $p = 0.25$, $0.30$, $0.50$, $0.60$, $0.90$, respectively, for Case (i-Cls); and the solid, short-dashed, dotted, dash-dotted, and long-dashed lines connect the dots, squares, diamonds, upward triangles, and downward triangles, respectively.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






Figure 4: For $x \neq 0$, the $x$-axis represents the day when an individual takes the second PCR test, and the $y$-axis the infection probability for an individual with a negative PCR test result on both day $0$ and day $x$, for Case (ii-Cls). For $x = 0$, the corresponding y value represents the infection probability for an individual with a negative PCR test result on day $0$, for Case (ii-Cls). The dots, squares, diamonds, upward triangles, and downward triangles show the infection probabilities for $p = 0.25$, $0.30$, $0.50$, $0.60$, $0.90$, respectively, for Case (ii-Cls); and the solid, short-dashed, dotted, dash-dotted, and long-dashed lines connect the dots, squares, diamonds, upward triangles, and downward triangles, respectively.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



# Tables

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Table 1: Time evolution of the distribution of people isolated on day 0, using the discrete SEIR model

| Status | $S$ | $E$ | | | $\mathcal{P}$ | | $I$ | | | | | | | $R$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| day | | $E_1$ | $E_2$ | $E_3$ | $\mathcal{P}_1$ | $\mathcal{P}_2$ | $I_1$ | $I_2$ | $I_3$ | $I_4$ | $I_5$ | $I_6$ | $I_7$ | |
| day 0 | $S_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\mathcal{P}_{1,0}$ | $\mathcal{P}_{2,0}$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $0$ |
| day 1 | $S_0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\mathcal{P}_{1,0}$ | $\mathcal{P}_{2,0}$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ |
| day 2 | $S_0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\mathcal{P}_{1,0}$ | $\mathcal{P}_{2,0}$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{2}{7}I_0$ |
| day 3 | $S_0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\mathcal{P}_{1,0}$ | $\mathcal{P}_{2,0}$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{3}{7}I_0$ |
| day 4 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\mathcal{P}_{1,0}$ | $\mathcal{P}_{2,0}$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{4}{7}I_0$ |
| day 5 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\mathcal{P}_{1,0}$ | $\mathcal{P}_{2,0}$ | $\frac{1}{7}I_0$ | $\frac{1}{7}I_0$ | $\frac{5}{7}I_0$ |
| day 6 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $P_{1,0}$ | $P_{2,0}$ | $\frac{1}{7}I_0$ | $\frac{6}{7}I_0$ |
| day 7 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $P_{1,0}$ | $P_{2,0}$ | $I_0$ |
| day 8 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $P_{1,0}$ | $P_{2,0}+I_0$ |
| day 9 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $P_{1,0}+P_{2,0}+I_0$ |
| day 10 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0$ | $\frac{1}{3}E_0+P_{1,0}+P_{2,0}+I_0$ |
| day 11 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $\frac{1}{3}E_0$ | $\frac{2}{3}E_0+P_{1,0}+P_{2,0}+I_0$ |
| day 12 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $E_0+P_{1,0}+P_{2,0}+I_0$ |
| day 13 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $E_0+P_{1,0}+P_{2,0}+I_0$ |
| day 14 | $S_0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $0$ | $E_0+P_{1,0}+P_{2,0}+I_0$ |

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Table 2: Accuracy of COVID-19 PCR tests

| Individual is \ Individual status | $S$ or $E$ | $P_1$ | $P_2$ | $I$ |
|---|---|---|---|---|
| infected | $1-b$ $=0.001$ | $a_1$ $=0.33$ | $a_2$ $=0.67$ | $a_I$ $=0.80$ |
| not infected | $b$ $=0.999$ | $1-a_1$ $=0.67$ | $1-a_2$ $=0.33$ | $1-a_I$ $=0.20$ |

Table 3: Accuracy of COVID-19 antigen tests

| Individual is \ Individual status | $S$ or $E$ | $P_1$ | $P_2$ | $I$ |
|---|---|---|---|---|
| infected | $1-b$ $=0.001$ | $0.7a_1$ $=0.23$ | $0.7a_2$ $=0.47$ | $0.7a_I$ $=0.56$ |
| not infected | $b$ $=0.999$ | $1-0.7a_1$ $=0.77$ | $1-0.7a_2$ $=0.53$ | $1-0.7a_I$ $=0.44$ |

Table 4: List of infection probabilities on day $k$ for an individual with a negative PCR test result on both day $0$ and day $k$. Note that the results at $k=0$ indicate the probabilities on day $0$ for an individual with a negative PCR test result on day $0$.

| $k$ | Case(i) | Case(ii) |
|---|---|---|
| 0 | 0.009811 | 0.008602 |
| 1 | 0.005810 | 0.005205 |
| 2 | 0.004386 | 0.003968 |
| 3 | 0.002959 | 0.002588 |
| 4 | 0.002098 | 0.001746 |
| 5 | 0.001739 | 0.001379 |
| 6 | 0.001690 | 0.001308 |
| 7 | 0.001642 | 0.001237 |
| 8 | 0.001386 | 0.001158 |
| 9 | 0.001037 | 0.0009855 |
| 10 | 0.0006905 | 0.0006561 |
| 11 | 0.0003448 | 0.0003276 |
| 12 | 0 | 0 |
| 13 | 0 | 0 |
| 14 | 0 | 0 |

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Table 5: Initial populations of close contact people who are isolated at the appearance of an individual with a positive PCR test result (Case (i-Cls)) or who is symptomatic (Case (ii-Cls), with various percentages of infected people in the close contact group ($p$).

| $p$ | Case | $P(S_0)$ | $P(E_0)$ | $P(Ia_{1,0})$ | $P(Ia_{2,0})$ | $P(Is_0)$ |
|---|---|---|---|---|---|---|
| $p = 0.25$ | Case(i-Cls) | 0.9808 | 0.005111 | 0.002550 | 0.003291 | 0.008218 |
| | Case(ii-Cls) | 0.9808 | 0.004851 | 0.001258 | 0.001024 | 0.01211 |
| $p = 0.30$ | Case(i-Cls) | 0.9770 | 0.006133 | 0.00306 | 0.003949 | 0.009862 |
| | Case(ii-Cls) | 0.9769 | 0.005821 | 0.001510 | 0.001229 | 0.01454 |
| $p = 0.50$ | Case(i-Cls) | 0.9617 | 0.01022 | 0.005100 | 0.006582 | 0.01644 |
| | Case(ii-Cls) | 0.9615 | 0.009701 | 0.002517 | 0.002048 | 0.02423 |
| $p = 0.60$ | Case(i-Cls) | 0.9540 | 0.01227 | 0.00612 | 0.007899 | 0.01972 |
| | Case(ii-Cls) | 0.9538 | 0.01164 | 0.003020 | 0.002457 | 0.02907 |
| $p = 0.90$ | Case(i-Cls) | 0.9310 | 0.01840 | 0.009181 | 0.01185 | 0.02959 |
| | Case(ii-Cls) | 0.9307 | 0.01746 | 0.004530 | 0.003686 | 0.04361 |

Table 6: nfection probability of an individual in Case (i-Cls) with a negative PCR test result on both day 0 and day $k$ ($k \geq 1$), under the assumption that the percentage of infected people in the close contact people is $p$. When $k = 0$, the table shows the infection probability of an individual in Case (i-Cls) with a negative PCR test result on day 0.

| | Case(i-Cls) | | | | |
|---|---|---|---|---|---|
| $k \mid p$ | $p = 0.25$ | $p = 0.30$ | $p = 0.50$ | $p = 0.60$ | $p = 0.90$ |
| 0 | 0.009811 | 0.01180 | 0.01981 | .02387 | 0.03622 |
| 1 | 0.005810 | 0.006991 | 0.01178 | 0.01421 | 0.02167 |
| 2 | 0.004386 | 0.005278 | 0.008901 | 0.01074 | 0.01641 |
| 3 | 0.002959 | 0.003562 | 0.006013 | 0.007262 | 0.01111 |
| 4 | 0.002098 | 0.002526 | 0.004267 | 0.005154 | 0.007891 |
| 5 | 0.001739 | 0.002093 | 0.003536 | 0.004272 | 0.006541 |
| 6 | 0.001690 | 0.002035 | 0.003437 | 0.004152 | 0.006356 |
| 7 | 0.001642 | 0.001977 | 0.003339 | 0.004033 | 0.006172 |
| 8 | 0.001386 | 0.001669 | 0.002815 | 0.003399 | 0.005195 |
| 9 | 0.001037 | 0.001248 | 0.002103 | 0.002538 | 0.003872 |
| 10 | 0.0006905 | 0.0008307 | 0.001398 | 0.001686 | 0.002568 |
| 11 | 0.0003448 | 0.0004147 | 0.0006972 | 0.0008404 | 0.001278 |
| 12 | 0 | 0 | 0 | 0 | 0 |
| 13 | 0 | 0 | 0 | 0 | 0 |
| 14 | 0 | 0 | 0 | 0 | 0 |

Table 7: Infection probability of an individual in Case (ii-Cls) with a negative PCR test result on both day 0 and day $k$ ($k \geq 1$), under the assumption that the percentage of infected people in the close contact people is $p$. When $k = 0$, the table shows the infection probability of an individual in Case (ii-Cls) with a negative PCR test result on day 0.

| | Case(ii-Cls) | | | | |
|---|---|---|---|---|---|
| $k \mid p$ | $p = 0.25$ | $p = 0.30$ | $p = 0.50$ | $p = 0.60$ | $p = 0.90$ |
| 0 | 0.008602 | 0.01034 | 0.01739 | 0.02096 | 0.03187 |
| 1 | 0.005205 | 0.006263 | 0.01056 | 0.01274 | 0.01944 |
| 2 | 0.003968 | 0.004776 | 0.008056 | 0.009726 | 0.01486 |
| 3 | 0.002588 | 0.003116 | 0.005260 | 0.006353 | 0.009719 |
| 4 | 0.001746 | 0.002102 | 0.003549 | 0.004288 | 0.006564 |
| 5 | 0.001379 | 0.001660 | 0.002804 | 0.003388 | 0.005186 |
| 6 | 0.001308 | 0.001575 | 0.002659 | 0.003212 | 0.004916 |
| 7 | 0.001237 | 0.001490 | 0.002514 | 0.003037 | 0.004646 |
| 8 | 0.001158 | 0.001394 | 0.002352 | 0.002840 | 0.004343 |
| 9 | 0.0009855 | 0.001186 | 0.002001 | 0.002415 | 0.003690 |
| 10 | 0.0006561 | 0.0007895 | 0.001330 | 0.001605 | 0.002448 |
| 11 | 0.0003276 | 0.0003941 | 0.0006633 | 0.0008000 | 0.001218 |
| 12 | 0 | 0 | 0 | 0 | 0 |
| 13 | 0 | 0 | 0 | 0 | 0 |
| 14 | 0 | 0 | 0 | 0 | 0 |

medRxiv preprint doi: https://doi.org/10.1101/2022.02.20.22270449; this version posted February 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Table 8: Infection probability of an individual with a negative PCR test result on day $0$ and a negative PCR or antigen test result on day $1$. The symbol $\Delta$ represents the difference in probability.

| | Case(i) | Case(ii) |
|---|---|---|
| PCR test at day $1$ | $0.005810$ | $0.005205$ |
| Antigen test at day $1$ | $0.006944$ | $0.006122$ |
| $\Delta$ | $+0.001134$ | $+0.0009170$ |

Table 9: Infection probability of an individual with a negative PCR test result on day $0$ and a negative PCR or antigen test result on day $1$. The symbol $\Delta$ represents the difference in probability, under the assumption the percentage of infected people in the close contact people is $p$.

| $p$ | Test type at day $1$ | Case(i-Cls) | Case(ii-Cls) |
|---|---|---|---|
| $p = 0.25$ | PCR | $0.005810$ | $0.005205$ |
| | Antigen test | $0.006944$ | $0.006122$ |
| | $\Delta$ | $+0.001134$ | $+0.0009170$ |
| $p = 0.30$ | PCR | $0.0069961$ | $0.006263$ |
| | Antigen | $0.08353$ | $0.007366$ |
| | $\Delta$ | $+0.001136$ | $+0.001103$ |
| $p = 0.50$ | PCR test | $0.01178$ | $0.01056$ |
| | Antigen test | $0.01406$ | $0.01241$ |
| | $\Delta$ | $+0.00228$ | $+0.00185$ |
| $p = 0.60$ | PCR test | $0.01421$ | $0.01274$ |
| | Antigen test | $0.01696$ | $0.01497$ |
| | $\Delta$ | $+0.00275$ | $+0.00223$ |
| $p = 0.90$ | PCR test | $0.02167$ | $0.01944$ |
| | Antigen test | $0.02582$ | $0.02281$ |
| | $\Delta$ | $+0.00415$ | $+0.00337$ |